Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

ATR12-351 ointment safely delivers LEKTI protein to the skin, reducing enzyme activity in Netherton syndrome.

In this study, patients with treatment-refractory alopecia areata who received oral ritlecitinib 50 mg daily experienced significant hair regrowth, with 52.6% achieving complete scalp regrowth and improved Severity of Alopecia Tool scores, indicating its potential effectiveness in real-world settings.

The trial helped find the best dose of deuruxolitinib for treating alopecia areata.

This study suggests that methotrexate use among rheumatoid arthritis patients is associated with patient-reported side effects and tolerability issues that may not be fully recognized by physicians.

This review discusses the emerging considerations and challenges of uterus transplantation for transgender women but presents no new clinical results.

This study observed that extracellular ATP is present in Medicago truncatula and correlates with regions of active cell growth, suggesting its integral role in plant development.

This article provides regulatory updates, legal briefs, and industry news, reporting no new clinical findings.

This study reports that topical ruxolitinib failed to induce hair growth in a 66-year-old patient with alopecia areata, highlighting the need to explore factors affecting treatment response and compare topical vs oral administration outcomes.

In this study, patients with alopecia areata who didn't initially respond to ritlecitinib at Week 24 showed improved response rates by Week 48, with up to 34% achieving better hair regrowth outcomes.

CTP-543 is generally safe for treating alopecia areata.

This systematic review reported that habit reversal training showed the most consistent benefit for treating pediatric trichotillomania, while evidence for pharmacological treatments and alternative therapies like N-acetylcysteine remains insufficient, highlighting the need for early behavioral intervention and further research into standardized treatment protocols.

The authors concluded that capecitabine and high-dose toremifene may be an effective treatment option for patients unable to undergo anthracycline or taxane therapies, based on one woman's cancer management.

This article discusses common skin side effects of EGFR inhibitors like cetuximab, noting their management remains based on clinical experience without strict therapy protocols, but provides no new clinical findings.

This study reported that patients with alopecia areata treated with ritlecitinib in a real-life setting had a higher rate of positive response on the Severity of Alopecia Tool score compared to those in the ALLEGRO trial.

This study reports that a 15-year-old with trichotillomania showed improvement with aripiprazole treatment, though no consensus on treatment exists in the literature.

This case study reports that low-dose testosterone therapy improved libido and sexual functions in a 36-year-old fragile X carrier female with hypoactive sexual desire disorder when monitored regularly for lab parameters.

This study found that among adolescents with alopecia areata and significant hair loss, treatment with ritlecitinib resulted in greater hair regrowth and self-reported improvement compared to placebo over 48 weeks, with common side effects including headache, acne, and nasopharyngitis.

In this study, early prenatal treatment with Minoxidil, a lysyl hydroxylase inhibitor, partly improved cardiac outflow tract septation in Tbx1 mutant mice, suggesting that inhibiting collagen cross-linking may mitigate some effects of Tbx1 mutation associated with DiGeorge syndrome.

This study found that the ablation of Esrp1 and Esrp2 disrupts epithelial tight junctions by affecting Arhgef11 isoform expressions, highlighting a potential mechanistic link between splicing alterations and epithelial barrier defects.

This study concluded that polymeric nanoparticles effectively targeted hair follicles for drug delivery, but the organogel formulation did not enhance their penetration into the hair shaft.

This study optimized a screening assay to identify molecules that inhibit or enhance TRPM5 ion channel activity, which may have implications for treating dysfunctions linked to cardiac arrhythmias and diabetes.

This review highlights recent progress in developing androgen receptor degraders, such as PROTACs, for treating castration-resistant prostate cancer, and notes that several have entered phase I or II clinical trials, showcasing potential to address drug resistance challenges.

Ritlecitinib works well and is safe for treating alopecia areata.

In this study, GTx-027, a selective androgen receptor modulator, significantly inhibited tumor growth in certain breast cancer models and showed good tolerance in a Phase II trial with postmenopausal women.

This review discusses the non-cosmetic uses of botulinum neurotoxin A, including its effectiveness for idiopathic hyperhidrosis and potential use for androgenic alopecia, and reports no new clinical results; the authors highlight the need for more clinical trials.

This study found that intralesional pentoxifylline injections were effective for localized alopecia areata, with the best results observed when combined with triamcinolone acetonide.